O’Melveny Advises Belite Bio on Upsized US$275 Million Private Placement Financing
September 11, 2025
FOR IMMEDIATE RELEASE
SHANGHAI—September 11, 2025—O’Melveny represented Belite Bio, Inc (Nasdaq: BLTE), a clinical-stage drug development company, in its upsized private placement financing of up to US$275 million with a syndicate of leading healthcare investors.
This private placement in public equity financing (“PIPE”) provides Belite Bio with US$125 million in upfront financing and the potential for an additional US$150 million through the exercise of accompanying warrants. It was led by RA Capital Management with participation from Eventide Asset Management, Marshall Wace, RTW Investments, Soleus Capital, and Vestal Point Capital. Morgan Stanley was the sole placement agent for the PIPE.
O’Melveny advised Belite Bio on all aspects of the PIPE transaction, including the structuring, negotiation, and execution of securities purchase agreements and related documentation.
The O’Melveny team was led by corporate partners Portia Ku and Vincent Lin, with support from associate Wuxiao Liang and legal consultants Nick Mu and Chris Wu. Partners Robert Plesnarski and James Harrigan advised on matters related to SEC regulations.
About O’Melveny
It’s more than what you do: it’s how you do it. Across sectors and borders, in board rooms and courtrooms, we measure our success by yours. And in our interactions, we commit to making your O’Melveny experience as satisfying as the outcomes we help you achieve. Our greatest accomplishment is ensuring that you never have to choose between premier lawyering and exceptional service. So, tell us. What do you want to achieve? Visit us at www.omm.com; learn more in our firm at-a-glance; and find us on LinkedIn, Facebook, Instagram, and YouTube.
Contact:
Brandon Jacobsen
O’Melveny & Myers LLP
+1 213 430 8024
bjacobsen@omm.com
Chris Schob
O’Melveny & Myers LLP
+86 21 2307 7000
cschob@omm.com
# # #